Fineline Cube

Follow:
14446 Articles
NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
CompanyDrug

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

FDA Approves J&J's IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
CompanyDrug

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

FDA Approves BeOne's Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
CompanyDrug

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

MHLW Approves Takeda's First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
CompanyDrug

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Company

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs

Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth
Company

Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
CompanyDeals

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

EC Approves Gilead's Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk
CompanyDrug

EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk

CompanyDeals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

GSK's Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027
CompanyDrug

GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027

CompanyLegal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%